DECHENG CAPITAL MANAGEMENT III CAYMAN LLC
Q3 2022 Form 13-F
GRAND CAYMAN, CAYMAN ISLANDS
CIK 0001747821
· Institutional investment manager
$275.8M Reported Value Total
Reported value
$275.8M
Quarter over quarter
-4.8%
Holdings
26
Top-10 concentration
79.0%
Key People
Named on the latest Form 13-F filing — not necessarily an owner
Jessie Qiu
Chief Compliance Officer
Filing Navigation
13F Metrics
Loading 13F Metrics
Q3 2022 13F record
Q3 2022 13F filing summary
| Period of report | September 30, 2022 |
|---|---|
| Filed | November 08, 2022 |
| Form | 13F-HR |
| Reported value | $275.8M |
| Positions | 26 |
| Change in reported value | +4.6% |
| New positions | 3 |
| Exited positions | 2 |
| Position turnover | 17.9% |
| Top-10 concentration | 79.0% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q3 2023 13F
Filed Nov 13, 2023
|
27 | $312.9M |
|
Q2 2023 13F
Filed Jul 28, 2023
|
25 | $318.8M |
|
Q1 2023 13F
Filed May 10, 2023
|
24 | $247.9M |
|
Q4 2022 13F
Filed Feb 9, 2023
|
26 | $267.2M |
|
Q3 2022 13F
Filed Nov 8, 2022
|
26 | $275.8M |
|
Q2 2022 13F
Filed Aug 1, 2022
|
25 | $263.7M |
|
Q1 2022 13F
Filed May 10, 2022
|
24 | $326.3M |
Top 20 holdings · Q3 2022
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | ALPN Alpine Immune Sciences, Inc. | $48.3M | 17.51% |
| 2 | ZNTL Zentalis Pharmaceuticals Inc. | $39.5M | 14.33% |
| 3 | HLTH Cue Health Inc. | $27.0M | 9.8% |
| 4 | ILMN Illumnia, Inc. | $24.8M | 9.0% |
| 5 | RCUS Arcus BioSciences, Inc. | $22.8M | 8.25% |
| 6 | RXDX Prometheus Biosciences, Inc. | $14.8M | 5.35% |
| 7 | ALBO Albireo Pharma, Inc. | $12.1M | 4.38% |
| 8 | TXG 10x Genomics, Inc. | $10.2M | 3.71% |
| 9 | EQ Equillium Inc. | $9.9M | 3.58% |
| 10 | PACB Pacific Biosciences of California, Inc. | $8.5M | 3.08% |
| 11 | ACET Adicet Bio, Inc. | $8.2M | 2.99% |
| 12 | WHWK Aadi Bioscience, Inc. | $7.4M | 2.7% |
| 13 | MRSN Mersana Therapeutics, Inc. | $6.1M | 2.22% |
| 14 | APGN Apexigen, Inc. | $5.1M | 1.85% |
| 15 | BYSI BeyondSpring Inc. | $4.9M | 1.78% |
| 16 | HZNP Horizon Therapeutics PLC | $4.9M | 1.77% |
| 17 | TERN Terns Pharmaceuticals, Inc. | $4.2M | 1.53% |
| 18 | AURA Aura Biosciences, Inc. | $3.8M | 1.38% |
| 19 | SGEN Seagen Inc. | $3.1M | 1.14% |
| 20 | WGS Sema4 Holings Corp. | $3.0M | 1.09% |
Values as reported on the Q3 2022 Form 13F. Every position is in the holdings table below.